Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

被引:0
作者
Shan Luo
Hugh Simon Lam
Yap Hang Chan
Clara Sze Man Tang
Baoting He
Man Ki Kwok
Gabriel M. Leung
C Mary Schooling
Shiu Lun Au Yeung
机构
[1] The University of Hong Kong,School of Public Health, Li Ka Shing Faculty of Medicine
[2] The Chinese University of Hong Kong,Department of Paediatrics, Faculty of Medicine
[3] Queen Mary Hospital,Division of Cardiology
[4] The University of Hong Kong,Department of Surgery, Li Ka Shing Faculty of Medicine
[5] The University of Hong Kong,Dr. Li Dak
[6] The University of Hong Kong,Sum Research Centre
[7] City University of New York,School of Public Health and Health Policy
来源
BMC Medicine | / 21卷
关键词
HMGCR inhibitors; PCSK9 inhibitors; Safety; Adolescents; Drug-target Mendelian randomization;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 170 条
[1]  
Luirink IK(2019)20-year follow-up of statins in children with familial hypercholesterolemia N Engl J Med 381 1547-1556
[2]  
Wiegman A(2017)Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults Lancet 390 2627-42
[3]  
Kusters DM(2016)Statin-associated side effects J Am Coll Cardiol 67 2395-2410
[4]  
Thompson PD(2008)Immortal time bias in pharmaco-epidemiology Am J Epidemiol 167 492-499
[5]  
Panza G(2019)Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects Circulation 140 270-279
[6]  
Zaleski A(2020)Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study Diabetologia 63 2349-2358
[7]  
Taylor B(2022)Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study BMC Med 20 288-662
[8]  
Suissa S(2022)Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function J Am Coll Cardiol 80 653-1327
[9]  
Gill D(2020)Evolocumab in pediatric heterozygous familial hypercholesterolemia N Engl J Med 383 1317-620
[10]  
Georgakis MK(2020)Genetic drug target validation using Mendelian randomisation Nat Commun 11 3255-1096